Combined hormone therapy and radiation therapy for locally advanced prostate cancer

The combination of radiotherapy and androgen suppression with luteinizing hormone releasing hormone agonist has become a standard of care for locally advanced prostate cancer. Phase III randomized trials have shown that for locally advanced prostate cancer a 4-month complete androgen blockade initiated 2 months prior radiotherapy and stopped at the completion of radiotherapy increased overall survival in patients with Gleason score 2–6, meanwhile an adjuvant long term androgen suppression (2.5–3 years) improved significantly overall survival.